<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05071183</url>
  </required_header>
  <id_info>
    <org_study_id>TPX-0005-13</org_study_id>
    <nct_id>NCT05071183</nct_id>
  </id_info>
  <brief_title>A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors</brief_title>
  <official_title>A Phase 1b/2 Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Advanced Solid Tumors (TRIDENT-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turning Point Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turning Point Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1b/2 Study of Repotrectinib in Combination with Other Anticancer Therapies for the&#xD;
      Treatment of Subjects with KRAS-Mutant Advanced Solid Tumors (TRIDENT-2)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1 Dose Escalation: To evaluate tolerability of repotrectinib at increasing dose levels&#xD;
      in combination with other anticancer therapies for the treatment of subjects with locally&#xD;
      advanced or metastatic KRAS-mutant solid tumors&#xD;
&#xD;
      Phase 2 Efficacy Evaluation: Investigate the anti-tumor efficacy and safety of repotrectinib&#xD;
      in combination with other anticancer therapies for the treatment of patients with locally&#xD;
      advanced or metastatic KRAS-mutant solid tumors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate Safety and Tolerability</measure>
    <time_frame>Three years</time_frame>
    <description>Evaluate the safety and tolerability of repotrectinib in combination with trametinib with treatment-related adverse events as assessed by CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Define the Recommended Phase 2 Dose (RP2D)</measure>
    <time_frame>Approximately 22 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Define the objective response rate (ORR)</measure>
    <time_frame>Two to three years after first dose of Repotrectinib in combination with other anticancer therapies</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum plasma concentration) of repotrectinib in combination with trametinib</measure>
    <time_frame>Up to 24 hours post-dose</time_frame>
    <description>Evaluate the maximum plasma concentration of repotrectinib in combination with trametinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (area under plasma concentration time curve) of repotrectinib in combination with trametinib</measure>
    <time_frame>Up to 24 hours post-dose</time_frame>
    <description>Determine the AUC of repotrectinib in combination with trametinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the preliminary efficacy of repotrectinib in combination with trametinib measured by ORR as assessed per RECIST v1.1</measure>
    <time_frame>Approximately three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (CBR)</measure>
    <time_frame>Approximately three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Approximately three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Approximately three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR)</measure>
    <time_frame>Approximately three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Approximately three years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>KRAS Mutation-Related Tumors</condition>
  <condition>Metastatic Solid Tumor</condition>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>TPX-0005 + Trametinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TPX-0005 + Trametinib Dose Escalation and Dose Expansion&#xD;
Dose escalation: KRAS G12D mutant advanced solid tumors. Dose expansion: KRAS G12D locally advanced or metastatic NSCLC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPX-0005</intervention_name>
    <description>Oral TPX-0005 capsules</description>
    <arm_group_label>TPX-0005 + Trametinib</arm_group_label>
    <other_name>repotrectinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib</intervention_name>
    <description>Oral trametinib tablets</description>
    <arm_group_label>TPX-0005 + Trametinib</arm_group_label>
    <other_name>Mekinist</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 (or as required by local regulation).&#xD;
&#xD;
          -  Histological or cytological confirmation of unresectable or metastatic solid tumor&#xD;
             malignancy harboring a KRAS mutation.&#xD;
&#xD;
          -  No more than 3 prior standard treatments appropriate for tumor type and stage of&#xD;
             disease.&#xD;
&#xD;
          -  ECOG performance status ≤ 1.&#xD;
&#xD;
          -  Existence of measurable disease (according to Response evaluation criteria in solid&#xD;
             tumors [RECIST v1.1] criteria).&#xD;
&#xD;
          -  Subjects with asymptomatic CNS metastases and/or asymptomatic leptomeningeal&#xD;
             carcinomatosis are eligible.&#xD;
&#xD;
          -  Adequate organ function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major surgery within four weeks of the start of treatment.&#xD;
&#xD;
          -  Previous other cancer requiring treatment within the previous two years.&#xD;
&#xD;
          -  Clinically significant cardiovascular disease.&#xD;
&#xD;
          -  Any of the following cardiac criteria:&#xD;
&#xD;
          -  Mean resting corrected QT interval (QTc) &gt; 470 msec obtained from three ECGs and any&#xD;
             factors that increase the risk of QTc prolongation or arrhythmic events&#xD;
&#xD;
          -  Any clinically important abnormalities in rhythm, conduction, or morphology of resting&#xD;
             ECG&#xD;
&#xD;
          -  Known clinically significant active infections not controlled with systemic treatment&#xD;
             (bacterial, fungal, viral including HIV positivity).&#xD;
&#xD;
          -  Gastrointestinal disease or other malabsorption syndromes that would impact drug&#xD;
             absorption.&#xD;
&#xD;
          -  Subjects being treated with or anticipating the need for treatment with strong CYP3A&#xD;
             inhibitors or inducers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Turning Point Therapeutics, MD</last_name>
    <role>Study Director</role>
    <affiliation>Turning Point Theraperutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Turning Point Therapeutics Call Center</last_name>
    <phone>(858) 276-0005</phone>
    <email>clinical@tptherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute at HealthONE</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerald Falchook, MD, MS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute at Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Johnson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Hong, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 13, 2021</study_first_submitted>
  <study_first_submitted_qc>October 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>KRAS</keyword>
  <keyword>KRAS-mutant</keyword>
  <keyword>Metastatic Solid Tumor</keyword>
  <keyword>Advanced Solid Tumor</keyword>
  <keyword>Advanced/metastatic disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

